Skip to main content
SpringerLink
Log in

Kein Nachteil durch Wechsel zwischen Biosimilar und Originator

  • Literatur kompakt
  • Published:
hautnah dermatologie Aims and scope

Die Sorge, bei Therapieumstellungen vom Originalbiologikum auf ein Nachahmerpräparat — und umgekehrt — könnten Wirksamkeit und Sicherheit leiden, ist für das Etanercept-Biosimilar GP2015 offenbar unbegründet.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Gerdes S et al. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. J Eur Acad Derm Venerol 2018; 32: 420–7

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Beate Schumacher

Authors
  1. Beate Schumacher
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schumacher, B. Kein Nachteil durch Wechsel zwischen Biosimilar und Originator. hautnah dermatologie 34, 28–29 (2018). https://doi.org/10.1007/s15012-018-2740-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-018-2740-7

Search

Navigation